Clinical Trial Update: Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC [NA]

View source ↗

Summary

An ongoing study sponsored by Fudan University is evaluating a combination of liposomal irinotecan and anlotinib as a second-line treatment for recurrent small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Fudan University | Conditions: Small Cell Lung Cancer Recurrent | NA | Status: RECRUITING